Orsenix Holdings BV
http://
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orsenix Holdings BV
Finance Watch: Days Of Reckoning As Biopharma Valuations, Fundraising Opportunities Fluctuate
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
Deal Watch: Merck & Co. Looks To Advance NASH Ambitions With Aligos
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Syros Goes For Reboot With New Investors And Leukemia Licensing
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals